Ki-67 [D2H10] Antibody – 153Eu

Catalog: 715301
Clone: D2H10

Isotype: Rabbit IgG

Reactivity: Human*

Application: MIBI-FFPE
Storage: Supplied in antibody stabilizer with 0.05% sodium azide. Store at 4°C

Ki-67-D2H10-IHC-staining-FFPE-human-tonsil
IHC: Ki-67 staining of FFPE human tonsil
Ki-67-D2H10-Ionpath-MIBI-staining-FFPE-human-tonsil
MIBI: Ki-67 staining (cyan) of FFPE human tonsil, costained with dsDNA (magenta)
Ki-67-D2H10-IHC-staining-FFPE-human-thymus
IHC: Ki-67 staining of FFPE human thymus
Ki-67-D2H10-Ionpath-MIBI-staining-FFPE-human-thymus
MIBI: Ki-67 staining (cyan) of FFPE human thymus, costained with dsDNA (magenta)

Background: Ki-67 is a nuclear protein expressed by proliferating cells (cells in G1, S, G2, and mitosis, absent in the G0 resting phase). The Ki-67 protein has a half-life of only 1–1.5 hours. The Ki-67 proliferation index, or fraction of Ki-67-positive tumor cells, is associated with the clinical course of certain cancers, including carcinomas of the prostate, brain and breast and gastroenteropancreatic neuroendocrine tumors. Antisense oligonucleotides and antibodies targeting Ki-67 have been reported to inhibit cell cycle progression.

Validation: Each lot of conjugated antibody is quality control tested by staining tissue following the MIBI Staining Protocol optimized for the applicable tissue format with subsequent MIBIscope analysis of stained tissue microarray using the appropriate positive and negative tissue field of views. These results are pathologist verified.

Recommended Usage: Human FFPE: 1:100 dilution.
For optimal results, the antibody should be titrated for each desired application.

MIBI technology: Learn more about MIBI Technology, a multiplex IHC technology with unmatched sensitivity and true subcellular resolution.

References
Li L.T., Jiang G., Chen Q., Zheng J.N. Ki67 is a promising molecular target in the diagnosis of cancer. Mol Med Rep. 2015;11(3):1566-72.
Rahmanzadeh, R., Rai, P., Celli, J.P., Rizvi, I., Baron-Lühr, B., Gerdes, J., Hasan, T. Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer. Cancer Res. 2010; 70(22):9234-42.

* Conjugate tested on human tissue.

Contact Us

Let us know how we can help you.


    Immuno-oncology/CancerNeuroscienceInfectious DiseaseImmunologyStem CellOther

    255

    X
    Contact Us

    We are using cookies on our website

    Please confirm, if you accept our tracking cookies. You can also decline the tracking and continue to visit our website without any data sent to third-party services.